Cancer Vaccination Drives Nanog-Dependent Evolution of Tumor Cells toward an Immune-Resistant and Stem-like Phenotype
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Noh, Kyung Hee | - |
dc.contributor.author | Lee, Young-Ho | - |
dc.contributor.author | Jeon, Ju-Hong | - |
dc.contributor.author | Kang, Tae Heung | - |
dc.contributor.author | Mao, Chih-Ping | - |
dc.contributor.author | Wu, T-C. | - |
dc.contributor.author | Kim, Tae Woo | - |
dc.date.accessioned | 2021-09-06T21:29:38Z | - |
dc.date.available | 2021-09-06T21:29:38Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012-04-01 | - |
dc.identifier.issn | 0008-5472 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/108742 | - |
dc.description.abstract | Due to the exquisite specificity and potency of the immune system, vaccination is in theory the most precise and powerful approach for controlling cancer. However, current data from clinical trials indicate that vaccination rarely yields significant benefits for cancer patients in terms of tumor progression and long-term survival. The poor clinical outcomes of vaccination are primarily caused by mechanisms of immune tolerance, especially within the tumor microenvironment. Here, we report that vaccination drives the evolution of tumor cells toward an immune-resistant and stem-like phenotype that promotes tumor growth and nullifies the CTL response. The emergence of this phenotype required the transcription factor Nanog, which is induced as a consequence of immune selection. Nanog expression enhanced the stem-like features of tumor cells and protected them from killing by tumor-reactive CTLs. Delivery of siNanog into tumor-bearing mice rendered the tumor vulnerable to immune surveillance and strongly suppressed its growth. Together, our findings show tumor adaptation to vaccination through gain of an immune-resistant, stem-like phenotype and identify Nanog as a central molecular target in this process. Future vaccination technology should consider Nanog an important target to enhance the immunotherapeutic response. Cancer Res; 72(7); 1717-27. (C)2012 AACR. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER ASSOC CANCER RESEARCH | - |
dc.subject | CLASS-II PRESENTATION | - |
dc.subject | ANTITUMOR IMMUNITY | - |
dc.subject | DENDRITIC CELLS | - |
dc.subject | T-CELLS | - |
dc.subject | ANTIGEN | - |
dc.subject | IMMUNOTHERAPY | - |
dc.subject | GENE | - |
dc.subject | IMMUNOSURVEILLANCE | - |
dc.subject | ENHANCEMENT | - |
dc.subject | EXPRESSION | - |
dc.title | Cancer Vaccination Drives Nanog-Dependent Evolution of Tumor Cells toward an Immune-Resistant and Stem-like Phenotype | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Noh, Kyung Hee | - |
dc.contributor.affiliatedAuthor | Kim, Tae Woo | - |
dc.identifier.doi | 10.1158/0008-5472.CAN-11-3758 | - |
dc.identifier.scopusid | 2-s2.0-84859417830 | - |
dc.identifier.wosid | 000302551800015 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH, v.72, no.7, pp.1717 - 1727 | - |
dc.relation.isPartOf | CANCER RESEARCH | - |
dc.citation.title | CANCER RESEARCH | - |
dc.citation.volume | 72 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1717 | - |
dc.citation.endPage | 1727 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | CLASS-II PRESENTATION | - |
dc.subject.keywordPlus | ANTITUMOR IMMUNITY | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | T-CELLS | - |
dc.subject.keywordPlus | ANTIGEN | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | IMMUNOSURVEILLANCE | - |
dc.subject.keywordPlus | ENHANCEMENT | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordAuthor | CLASS-II PRESENTATION | - |
dc.subject.keywordAuthor | ANTITUMOR IMMUNITY | - |
dc.subject.keywordAuthor | DENDRITIC CELLS | - |
dc.subject.keywordAuthor | T-CELLS | - |
dc.subject.keywordAuthor | ANTIGEN | - |
dc.subject.keywordAuthor | IMMUNOTHERAPY | - |
dc.subject.keywordAuthor | GENE | - |
dc.subject.keywordAuthor | IMMUNOSURVEILLANCE | - |
dc.subject.keywordAuthor | ENHANCEMENT | - |
dc.subject.keywordAuthor | EXPRESSION | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.